Severity of medial temporal atrophy and amnestic mild cognitive impairment: selecting type and number of memory tests

David A Loewenstein1, Amarilis Acevedo, Elizabeth Potter

  • 1Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach, FL 33140, USA. dloewenstein@att.net

Abstract

Insights

The Fuld Object Memory Evaluation (FOME) strongly correlates with medial temporal lobe atrophy (MTA), a key biomarker for memory decline. This memory test showed minimal impact from education levels, making it a reliable measure.

Area of Science:

  • Neuroimaging and Cognitive Neuroscience
  • Biomarker Development
  • Episodic Memory Research

Background:

  • Medial temporal lobe atrophy (MTA) serves as a biomarker for pathologies impacting episodic memory.
  • Understanding the relationship between specific memory tests and MTA is crucial for accurate cognitive assessment.

Purpose of the Study:

  • To compare the efficacy of four memory measures as biomarkers of MTA.
  • To investigate the influence of demographic factors (age, education, language) on memory performance and MTA.
  • To identify the most robust memory assessment for detecting MTA-related changes.

Main Methods:

  • 281 subjects with varying cognitive statuses (cognitively normal, MCI, dementia) underwent memory testing.
  • Memory assessments included the Hopkins Verbal Learning Test-revised, Fuld Object Memory Evaluation (FOME), story recall, and visual reproduction.
  • Medial temporal lobe atrophy (MTA) was quantified via visual rating of the hippocampus, entorhinal cortex, and perirhinal cortex on MRI scans.

Main Results:

  • Age was significantly associated with all memory measures and MTA.
  • The Fuld Object Memory Evaluation (FOME) demonstrated the strongest association with MTA, explaining 31% of the variability.
  • Among individuals with mild cognitive impairment (MCI), a higher number of impaired memory tests predicted greater MTA severity.

Conclusions:

  • The Fuld Object Memory Evaluation (FOME) is a highly sensitive measure for detecting medial temporal lobe atrophy (MTA).
  • FOME performance was minimally affected by educational background, enhancing its utility across diverse populations.
  • Assessing impairment across multiple memory tests provides a more accurate prediction of MTA than single-test impairment.

Related Concept Videos

Amnesia01:13

Amnesia

Amnesia is a condition marked by long-term memory loss, which impairs the ability to recall past events or create new memories.
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...